The Panadea CCHFV (NP) IgG ELISA Kit (Research Use Only) allows the qualitative detection of human serum/plasma IgG antibodies directed against the Crimean-Congo Hemorrhagic Fever Virus (CCHFV) nucleocapsid protein (NP) in 96-well (12x8) format. The test is based on a patented immune complex capture principle.
Determination of the presence/absence of IgG antibodies directed against CCHFV NP in human serum
IgG immune complex ELISA utilizing patented CD32 capture technology
Microwell plate (96 tests)
Surveillance of Crimean-Congo Hemorrhagic Fever Virus prevalence through screening of population samples for antibodies against the virus has importance not only for populations where the disease is known to circulate, but also for public health system preparedness on a world-wide level. As CCHFV can spread from person to person via contact of blood and other bodily fluids, the detection of the CCHF virus in a population is important for the prevention of outbreaks.
IgG antibodies persist in the blood of infected individuals long after the person has recovered from the viral infection. Surveillance studies employing IgG detection are critical for detecting CCHFV in human and ruminant populations without the requirement for the screened individuals to have clinically presented with suspicious symptoms and sampled during the transient period when they contain live virus. This makes IgG detection a valuable tool for observing the prevalence of a virus in a population, especially in Low- and Middle-Income Countries (LMIC), where infections with CCHFV are less likely to be correctly identified at the primary healthcare level.
FAQ Question 3 answer.
FAQ Question 4 answer.
FAQ Question 5 answer.
Have more questions?
Fill out our contact form and we'll get back to you.
